-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Inhibikase Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2020 to Q3 2024.
- Inhibikase Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$5.83M, a 22.2% decline year-over-year.
- Inhibikase Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$20.1M, a 0.21% decline year-over-year.
- Inhibikase Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$20.1M, a 10.8% decline from 2022.
- Inhibikase Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$18.1M, a 22.8% decline from 2021.
- Inhibikase Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$14.8M, a 424% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)